Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

FDA Struggles to Hire Overseas Drug Facility Inspectors

From 2016 to 2018, the FDA’s overseas drug facility inspections decreased by about 10%, in part because the agency has struggled to hire new...

FDA Approves Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

The FDA has granted accelerated approval to zanubrutinib, an inhibitor of Bruton tyrosine kinase (BTK), to treat adults with mantle cell lymphoma who have...
Sickle cell anemia

Crizanlizumab-tmca Becomes First Approved Targeted Therapy for Sickle Cell Disease

The FDA approved crizanlizumab-tmca to reduce the frequency of vaso-occlusive crisis in patients aged 16 and older with sickle cell disease (SCD). The agent...

Gene Editing Therapy Shows Early Benefit for Patients With SCD and Beta Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals have reported that the first two patients to receive an experimental gene editing treatment for SCD and beta thalassemia...

Luspatercept-aamt Approved to Treat Anemia in Beta Thalassemia

The FDA approved luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. The approval...

FDA Expands Rivaroxaban’s Indication to Include Hospitalized Patients

The U.S. Food and Drug Administration (FDA) approved the direct oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill...

National Academy of Medicine Releases Report on Clinician Burnout

In a newly published report, the National Academy of Medicine called for systematic changes from health care organizations, educational institutions, and all levels of...

Updated Romiplostim Label Supports Earlier Use in ITP

The U.S. Food and Drug Administration (FDA) granted approval to a supplemental Biologics License Application for romiplostim that updates the drug’s label to include...

Vincristine Shortages Expected to Continue Into 2020

The U.S. is experiencing a shortage of the chemotherapy drug vincristine, a critical treatment for leukemias, lymphomas, and brain tumors in adult and pediatric...

European Commission Approves Gilteritinib for FLT3-Mutated, Relapsed/Refractory AML

The European Commission approved the oral FLT3/AXL inhibitor gilteritinib as a single agent for the treatment of adult patients with relapsed or refractory acute...
Advertisement

Current Issue

May 2020, Volume 6, Issue 6

This issue discusses AI's potential to improve patient care, debates using donors with clonal hematopoiesis for alloHCT, and more.